Business Monitor International


Slovenia Pharmaceuticals & Healthcare Report

Published 21 February 2014

  • 88 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Slovenia Pharmaceuticals & Healthcare Report

BMI View: Recapitalisation of Slovenia's banks this year will continue to constrain budgets, with significant pressure on public healthcare spending. The country should benefit from an uptick in the regional economic outlook, though country's unemployment rate and deleveraging by government and corporat ions will continue to put significant strain on the ZZZS, which is primarily dependent on insurance contributions. Spending cuts, pay freezes and price reductions for pharmaceuticals are all measures that could be employed to reduce the deficit. The pharmaceutical sector faces the prospect of price ceilings and further cost-cutting measures. As a result, we continue to believe pharmaceutical and healthcare spending will not show real growth until 2015 at the earliest.

Headline Expenditure Projections

  • Pharmaceuticals: EUR720mn (US$950mn) in 2013 to EUR730mn (US$920mn) in 2014; +0.7% in local currency terms and -3.1% in US dollar terms.

  • Healthcare: EUR3.22bn (US$4.25bn) in 2013 to EUR3.18bn (US$4.04bn) in 2014; -1.1% in local currency terms and -4.8% in US dollar terms.

Risk/Reward Rating

Slovenia's Pharmaceutical Risk/Reward Rating score for Q214 stands at 50.9 out of a total of 100, just below the regional average of 51.5. A worsening economic outlook has impacted Slovenia's RRR score.

Key Trends & Developments

  • In October 2013, four Slovenian drugmakers were accused of forming a drug cartel to manipulate wholesale drug prices in the country. The Competition Protection Agency (AVK) ruled that Kemofarmacija, Salus, Farmadent and Hopharm had colluded on the tender for the supply of drugs to public institutions and procurement of medicines for public pharmacy institutes. Although the four companies were charged for setting the prices of medicines at the highest permissible level at all times, they insist they did not breach competition laws in the country.

  • In October 2013 the Ministry of Health and the Health Institute of Slovenia (ZZZS) rolled out...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Slovenia Pharmaceutical Sales, Historical Data And Forecasts
15
Healthcare Market Forecast
16
Table: Slovenia Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: Slovenia Government Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: Slovenia Private Healthcare Expenditure Trends, Historical Data And Forecasts
18
Prescription Drug Market
18
Table: Slovenia Prescription Drug Market Indicators, Historical Data And Forecasts
19
Patented Drug Market Forecast
20
Table: Slovenia Patented Drug Market Indicators, Historical Data And Forecasts
21
Generic Drug Market Forecast
22
Table: Slovenia Generic Drug Market Indicators, Historical Data And Forecasts
23
OTC Medicine Market Forecast
24
Table: Slovenia Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
25
Pharmaceutical Trade Forecast
25
Table: Slovenia Pharmaceutical Trade Data And Forecasts (US$mn)
26
Table: Slovenia Pharmaceutical Trade Data And Forecasts (EURmn)
27
Key Risks To BMI's Forecast Scenario
28
Macroeconomic Forecasts
29
Economic Analysis
29
Table: Slovenia - Economic Activity
32
Industry Risk Reward Ratings
33
Central And Eastern Europe Risk/Reward Ratings
33
Slovenia Risk/Reward Ratings
39
Rewards
39
Risks
39
Market Overview
41
Industry Trends And Developments
43
Epidemiology
43
Healthcare Sector
44
Regulatory Development
47
Intellectual Property Regime
48
Pricing Regime
48
Reimbursement Regime
50
Competitive Landscape
53
Pharmaceutical Industry
53
Recent Pharmaceutical Industry Developments
54
Company Profile
55
Krka
55
Lek (Novartis/Sandoz)
60
GlaxoSmithKline (GSK)
64
Sanofi
67
Pfizer
69
Novartis
72
Merck & Co
75
Demographic Forecast
77
Table: Slovenia's Population By Age Group, 1990-2020, 1990-2020 ('000)
78
Table: Slovenia's Population By Age Group, 1990-2020 (% of total)
79
Table: Slovenia's Key Population Ratios, 1990-2020
80
Table: Slovenia's Rural And Urban Population, 1990-2020
80
Glossary
81
Methodology
83
Pharmaceutical Expenditure Forecast Model
83
Healthcare Expenditure Forecast Model
83
Notes On Methodology
84
Risk/Reward Ratings Methodology
85
Ratings Overview
86
Table: Pharmaceutical Risk/Reward Ratings Indicators
86
Indicator Weightings
87

The Slovenia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Slovenia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovenian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Slovenia to test other views - a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Slovenian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovenia.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc